autoclaved leishmania antigen + recombinant human interleukin-12 + aluminum hydroxide

autoclaved leishmania antigen + recombinant human interleukin-12 + aluminum hydroxide is a combination vaccine candidate developed by the National Institute of Allergy and Infectious Diseases (NIAID) for the prevention or treatment of cutaneous leishmaniasis. The vaccine consists of heat-killed (autoclaved) *Leishmania* parasites, which serve as the source of antigens, combined with two adjuvants: recombinant human interleukin-12 (rhIL-12) and aluminum hydroxide gel (alum). rhIL-12 is included to specifically promote a Th1-type cell-mediated immune response, which is essential for the clearance of intracellular *Leishmania* parasites, while alum enhances the overall immunogenicity. This formulation was designed to provide a safer and more standardized alternative to leishmanization, the traditional practice of inoculating live parasites.

Other names

heat-killed leishmania vaccineALA/rhIL-12/alum vaccine